<DOC>
	<DOCNO>NCT02083887</DOCNO>
	<brief_summary>Two vaccine , ChAd63 ME-TRAP MVA ME-TRAP , test see form safe effective vaccination strategy malaria . The vaccine find well tolerate test Gambian adult , young child infant , risk severe malaria . Both vaccine give participate infant time EPI ( Expanded Program Immunization ) vaccine , ass whether safe still helpful make body 's defense system respond .</brief_summary>
	<brief_title>A Phase I Study Assess Safety Immunogenicity ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines Gambian Infants</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Group 1 : 15 healthy infant age 16 week time enrolment sign consent obtain parent Group 2 : 15 healthy infant age 8 week time enrolment sign consent obtain parent Group 3 : 15 healthy infant age 1 week time enrolment sign consent obtain parent Group 4 ( control ) : 20 healthy infant age 16 , 8 1 week time enrolment sign consent obtain parent Groups 1 2 : Receipt EPI vaccine accord schedule define follow : Bacillus CalmetteGuérin ( BCG ) , first dose oral polio ( OPV ) Hepatitis B vaccine within 2 week birth ; Penta , pneumococcal vaccine , OPV , rotavirus vaccine Group 1 8 week +/ 2 week Birth weight less 2.5kg Significant antenatal , perinatal early postnatal complication judge PI delegate individual Any sign acute illness judge PI delegate individual Axillary temperature great 37.5 °C Clinically significant congenital abnormality judge PI delegate individual Clinically significant history skin disorder ( psoriasis , contact dermatitis etc . ) , allergy , symptomatic immunodeficiency , cardiovascular disease , respiratory disease , endocrine disorder , liver disease , renal disease , gastrointestinal disease , neurological illness judge PI delegate individual . Weight age zscores 2 standard deviation normal age History allergic disease reaction likely exacerbate component vaccine , e.g . egg product , Kathon , neomycin , betapropiolactone . History splenectomy Haemoglobin le 10 g/dL &gt; 4 week age le 13.0 g/dl &lt; 4 week age . White cell count &lt; 5.0 x 109/L Serum Creatinine concentration great 60 micromol/L , Serum alanine aminotransferase ( ALT ) concentration great 45 U/L , Clinically significant jaundice Any clinically significant laboratory abnormality judge PI delegate individual Blood transfusion within one month enrolment . History vaccination previous experimental malaria vaccine . Administration immunoglobulin less two week vaccination IMPs Current participation another clinical trial , within 12 week study . Any finding opinion PI delegate individual would increase risk adverse outcome participation trial . Likelihood travel away study area Maternal HIV infection ( negative maternal HIV test require prior study enrolment ) Positive malaria antigen test screening</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Immune response</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Malaria</keyword>
</DOC>